The great quarter was driven by high demand for sleep-related products and growth in digital health solutions. As a specialist in sleep and respiratory health, ResMed built its reputation through ...
UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback